XML 44 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands).

 

 

Twelve Months Ended
December 31, 2023

 

 

Twelve Months Ended
December 31, 2022

 

 

 

Beginning of period

 

 

End of period

 

 

Beginning of period

 

 

End of period

 

Cash and cash equivalents

 

$

114,846

 

 

$

188,657

 

 

$

147,435

 

 

$

114,846

 

Restricted cash

 

 

5,770

 

 

 

5,770

 

 

 

5,770

 

 

 

5,770

 

Total cash, cash equivalents and restricted
   cash shown in the statements of cash flows

 

$

120,616

 

 

$

194,427

 

 

$

153,205

 

 

$

120,616

 

Schedule of Estimated Useful Lives by Major Asset Category

Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Leasehold improvements are amortized over the shorter of their estimated useful lives or the term of the lease by use of the straight-line method. Construction-in-process reflects amounts incurred for property, equipment or improvements that have not been placed in service. Maintenance and repair costs are expensed as incurred. When assets are retired or sold, the assets and accumulated depreciation are removed from the respective accounts and any gain or loss is recognized. Estimated useful lives by major asset category are as follows:

 

 

Useful Lives

Machinery and equipment

 

5 to 7 years

Computers and software

 

3 years

Furniture and fixtures

 

10 years

Schedule of revenue consist of product sales to customers

The Company operates in one business segment. Results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues consist of net product sales to customers, all of which are sales in the U.S. Revenues by product are as follows (in thousands):

 

 

Years Ended December 31,

 

 

 

2023

 

 

2022

 

 

2021

 

NUPLAZID

 

$

549,248

 

 

$

517,235

 

 

$

484,145

 

DAYBUE

 

 

177,189

 

 

 

 

 

 

 

   Product sales, net

 

$

726,437

 

 

$

517,235

 

 

$

484,145

 

 

Weighted-Average Assumptions Used to Estimate Fair Value of Employee Stock Options The estimated fair value of each stock option and purchase right is then expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The following weighted-average assumptions were used during these periods:

 

 

Years Ended December 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Stock Options:

 

 

 

 

 

 

 

 

 

Expected volatility

 

 

66

%

 

 

68

%

 

 

64

%

Risk-free interest rate

 

 

3.9

%

 

 

2.9

%

 

 

0.9

%

Expected dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

Expected life of options in years

 

 

5.4

 

 

 

5.4

 

 

 

5.4

 

Weighted-Average Assumptions Used to Estimate Fair Value of Employee Stock Purchase Plan Rights

 

 

Years Ended December 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Employee Stock Purchase Plan:

 

 

 

 

 

 

 

 

 

Expected volatility

 

40%-67%

 

 

62%-82%

 

 

49%-100%

 

Risk-free interest rate

 

4.0%-5.3%

 

 

1.5%-4.6%

 

 

0.0%-0.5%

 

Expected dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

Expected life in years

 

0.5-2.0

 

 

0.5-2.0

 

 

0.5-2.0

 

Summary of Stock-based Compensation Expense Included in Statements of Operations

The table below summarizes the total stock-based compensation expense included in the Company’s consolidated statements of operations for the periods presented (in thousands):

 

 

Years Ended December 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Cost of product sales

 

$

1,007

 

 

$

1,106

 

 

$

1,286

 

Research and development

 

 

17,408

 

 

 

22,580

 

 

 

21,969

 

Sales, general and administrative

 

 

48,006

 

 

 

44,515

 

 

 

40,360

 

 

 

$

66,421

 

 

$

68,201

 

 

$

63,615